Abstract 146P
Background
Improving survival of cancer patients could be achieved by enhancing anti-tumor immunity which is frequently suppressed. Adenosine, found at high concentrations in most solid tumors, is reported to be a key mediator of immune suppression. Current drugs that target a key immune system switch, the adenosine 2A receptor (A2AR), are confronted with developmental hurdles related to their conventional (orthosteric) molecular mode of action, which cannot modulate A2AR signaling in immunosuppressive solid tumor microenvironment without safety concerns.
Methods
A drug discovery campaign at University of Geneva identified, and improved the potency of, orally bioavailable, non-brain penetrant, small molecule negative allosteric modulators (NAM) of A2AR. Optimized lead drug candidates were evaluated for safety, pharmacokinetics, and pharmacodynamics (target engagement, immune response restoration and tumor growth control) using in vitro, ex vivo, and in vivo models.
Results
A2AR NAMs displayed an excellent safety profile using industry-standard in vitro assays, and when administered to mice. The drug candidates fully restored anti-tumor cytokine secretion in primary human PBMC subsets, outperforming existing A2AR antagonists which have been tested in phase I or II human trials. A2AR NAMs were detected in mouse plasma at therapeutic concentrations after administration via the oral or subcutaneous routes. When tested in high adenosine mouse tumor models such as MC38 and CT26, A2AR NAMs significantly reduced tumor growth as a single agent immunotherapy, outperforming PD-1 immune checkpoint blockade as well as a small molecule A2AR drug candidate currently in Ph-II clinical development.
Conclusions
A2AR NAMs have an excellent safety and efficacy profile in translational assays and biologically relevant mouse tumor models, presumably stemming from their novel allosteric molecular mode of action. The drug candidates represent a next generation approach to A2AR blockade, which are intended to enhance the immune system and favor positive responses in solid tumor patients, especially when used in combination with other standard and immune-based cancer therapies.
Legal entity responsible for the study
University of Geneva.
Funding
Innosuisse.
Disclosure
D. Pejoski, H. Hamed: Financial Interests, Institutional, Member of Board of Directors: Adoram Therapeutics. M. Boujut: Financial Interests, Institutional, Stocks/Shares: Adoram Therapeutics. L. Scapozza: Financial Interests, Institutional, Advisory Role: Adoram Therapeutics. All other authors have declared no conflicts of interest.
Resources from the same session
26P - Liquid biopsy as promising source of plasma extracellular vesicle biomarkers of response to Cabozantinib (CABO) plus Durvalumab (DURVA) in advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) patients (the Phase 2 ARCADIA trial)
Presenter: Veronica Huber
Session: Poster Display
27P - Peripheral biomarker analysis in patients with advanced urothelial carcinoma (UC) after platinum chemotherapy treated with Cabozantinib (CABO) plus Durvalumab (DURVA): preliminary analysis from the Phase 2 ARCADIA trial.
Presenter: Francesco Sgambelluri
Session: Poster Display
28P - 3-year follow-up analysis of disease-free survival in CheckMate 274 by PD-L1 expression using tumor cell and combined positive scoring algorithms
Presenter: Frank Stenner-Liewen
Session: Poster Display
30P - CD4+ T cells within the tumor microenvironment are an independent predictor of recurrence, but do not improve the performance of a predictive model in oral squamous cell carcinoma
Presenter: Sangeeta Bisheshar
Session: Poster Display
31P - Characterization of pre-exhausted / exhausted state of CD8+ T cells in HRAS mutant head and neck carcinomas (HNSCCs). Implications for response to immune checkpoint blockade (ICB).
Presenter: Ioannis Kotsantis
Session: Poster Display
32P - Tumor-agnostic plasma assay for circulating tumor DNA predicts outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor
Presenter: Natasha Honoré
Session: Poster Display
34P - Heterogeneous response to Immune Checkpoint Inhibitors in metastatic melanoma patients - assessment of lesion-level response with 18F-FDG PET/CT
Presenter: Katja Strasek
Session: Poster Display